Diphenyl 1-amino-2-phenylethylphosphonate was introduced to poly(ethylene glycol)s (PEGs) with average molecular masses of 300, 400, and 600 to prepare waterinsoluble PEG-inhibitor conjugates. Interestingly, only the conjugate from PEG with an average molecular weight of 600 formed a precipitate with chymotrypsin but not with trypsin. The results demonstrated that the PEG-inhibitor conjugate is useful for separation of chymotrypsin.
Diphenyl a-aminoalkylphosphonates are known to irreversibly and speciˆcally inactivate serine proteases. 1) Since diphenyl a-aminoalkylphosphonates are relatively stable in aqueous solution, Powers et al. succeeded in the synthesis of their conjugates with biotin or ‰uorescent compounds useful for investigation of localization of intracellular serine proteases. 2) Legendre et al. developed a selection strategy for phage-displayed enzymes using a biotinylated phosphonate inhibitor and a streptoavidin-coated support.
3) Moreover, we recently prepared a Phe-type diphenyl a-aminoalkylphosphonate derivative that irreversibly inactivated chymotrypsin-like serine proteases and immobilized them on Sepharose gel (Pharmacia Biotech, Uppsala, Sweden), and we demonstrated that chymotrypsin could be separated from a solution containing chymotrypsin and trypsin by using an inhibitor-immobilized gel. 4) However, in this case, the diphenyl a-aminoalkylphosphonate derivative had to be prepared and puriˆed by silicagel chromatography before its immobilization on Sepharose gel. These steps required for the preparation of the inhibitor immobilized-Sepharose gel often led to a decrease in its e‹ciency to bind to chymotrypsin.
In this study, in order to develop an e‹cient method for an a‹nity separation system for serine proteases, the Phe-type phosphonate inhibitor moiety (diphenyl 1-amino-2-phenylethylphosphonate) was introduced into poly(ethylene glycol)s (PEGs) with diŠerent average molecular masses to give PEGinhibitor conjugates ( Fig. 1 ; 3 and 4), and then the binding abilities of chymotrypsin and trypsin to the obtained PEG-inhibitor conjugates were evaluated. PEGs are hydrophilic and water-soluble, whereas the Phe-type phosphonate inhibitor moiety is hydrophobic and water-insoluble. Thus, PEG-inhibitor conjugates are expected to be water-insoluble but adequately hydrophilic for enzyme accessibility. The PEG-inhibitor conjugates were synthesized in two steps, as shown in Fig. 1 . In theˆrst step, carbamoyl groups were introduced into the terminal hydroxy groups in PEGs to give the PEG carbamates as previously described. 5) For the preparation of the PEG300-inhibitor conjugate, PEG300 and sodium cyanate were mixed in tetrahydrofuran. Tri‰uoroa-cetic acid was then gently added and the reaction was allowed to proceed overnight at room temperature. The PEG300 carbamate produced was extracted with CHCl3 followed by evaporation under reduced pressure. In the second step, the Phe-type phosphonate inhibitor moiety was introduced into the PEG300 carbamate according to the a-amidoalkylation method using triphenyl phosphite, as described by Oleksyszyn et al.
6) The PEG300 carbamate was reacted with triphenyl phosphite and phenylacetaldehyde for three hours at 809 C in acetic acid. After partial puriˆcation by silica gel chromatography, the product obtained was treated with water to give the desired water-insoluble PEG300-inhibitor conjugate. The water-insoluble PEG400-and PEG600-inhibitor conjugates were also prepared by a similar procedure. All of the PEG carbamates from PEG300, PEG400, and PEG600 were obtained in 50-80z yields. When the PEG300, PEG400, and PEG600 carbamates (0.18, 0.24, and 0.34 g, respectively) were used in the amidoalkylation reaction of triphenyl phosphite to prepare the corresponding PEG-inhibitor conjugates, their yields after puriˆcation by silica gel chromatography were 0.25, 0.31, and 0.35 g, respectively. After subsequent treatment with water, 0.14, 0.16, and 0.02 g of the desired water-insoluble PEG300-, PEG400-, and PEG600-inhibitor conjugates were obtained, respectively.
The measurement of PEG carbamates and PEGinhibitor conjugates were done by 1 H-, 13 C-, 31 PNMRs, IR, and MALDI-TOF-MS. The PEG300, 400, and 600 carbamates were characterized by disappearance of terminal OH peaks (about 3.0 ppm) on 1 H NMR spectra, appearance of carbonyl carbon (157 ppm) on 13 C NMR spectra, and appearance of IR bands of N-H (3450-3200 cm -1 ), C＝O (1790, 1729 cm -1 ) and R-CH2-O-C＝O (1164 cm -1 ). The PEG300, 400, and 600-inhibitor conjugates were characterized by the appearance of b-CH2 (3.0-3.1, 3.4-3.5 ppm) and phenyl groups (7.1-7.3 ppm) on 1 H NMR spectra, the existence of phosphonate (17.0 ppm) on 31 P NMR spectra, and appearanace of IR bands of NH (3293 cm -1 ), phenyl (1593, 1491, 762, 696 cm -1 ), P-O-C and P＝O (1241, 1212, 1191, 1161, 940 cm -1 ). The PEG300-and PEG400-inhibitor conjugates were found to show molecular mass peaks at 624-876 and 770-1008, respectively, by MALDI-TOF-MS analysis. Since the Phe-type phosphonate moiety has a molecular mass of 352, most of the obtained water-insoluble PEG300-and PEG400-inhibitor conjugates should have one phosphonate inhibitor moiety per conjugate molecule, like the conjugate 3 shown in Fig. 1 . On the other hand, the PEG600-inhibitor conjugate showed a distribution of several molecular mass peaks (901-1032, 1164-1283, and 1388-1506), suggesting that one or two phosphonate moieties were introduced into one PEG600 carbamate molecule. Thus the obtained water-insoluble PEG600-inhibitor conjugate was found to contain two components corresponding to the conjugates 3 and 4 shown in Fig. 1 .
To examine whether the PEG300, 400, and 600-inhibitor conjugates can selectively separate serine proteases, these conjugates were mixed with chymotrypsin. Each PEG-inhibitor conjugate (1 mg) was dissolved in 0.1 ml of DMSO to prepare its stock solution. The obtained PEG-inhibitor conjugate stock solution (10 ml) was mixed with 90 ml of chymotrypsin solution (0.3 mg W ml of 20 mM TrisHCl buŠer, pH 7.0) and incubated for 20 min at 259 C. After the reaction mixtures were centrifuged to separate insoluble components, a portion (20 ml) of the supernatants was analyzed by a gel-ˆltration HPLC. Gel-ˆltration chromatograms of the remaining soluble components after mixing of chymotrypsin solution with the PEG-inhibitor conjugates are shown in Fig. 2A -C. Chymotrypsin and DMSO (control) peaks are seen at 12.5 and 25.0 min, respectively. Other peaks observed at 19-23 min may be due to by-products from the reaction between chymotrypsin and the PEG-inhibitor conjugates. After mixing of chymotrypsin solution with the PEG300-and PEG400-inhibitor conjugates at 259 C, 57 and 84z of the chymotrypsin peaks still remained, compared to those observed for the controls without mixing with the conjugates, respectively ( Fig. 2A and 2B ). Under these conditions, however, the remaining activity of chymotrypsin was decreased by mixing both with the PEG300-and PEG400-inhibitor conjugates, 10z and 40z, respectively (data not shown). This implies that the PEG300-and PEG400-inhibitor conjugates can inactivate chymotrypsin but that the obtained complex is soluble in the buŠer solution. On the other hand, both the remaining chymotrypsin peak and activity in the supernatant almost disappeared after mixing with For gelˆltration, a TSKgel G2000SW XL column (Tosoh, Japan) was used with 45z acetonitrile containing 0.1z TFA as a mobile phase. The elution was monitored at 280 nm, and the ‰ow rate and the column temperature were 0.5 ml W min and 259 C, respectively. Chymotrypsin and DMSO were eluted at 12.2 (a) and 25.0 min (b), respectively. Each remaining chymotrypsin content was estimated from a comparison between chymotrypsin peaks before (control) and after mixing with the corresponding conjugate using the DMSO peak as an internal standard. Reversed phase chromatography for the enzyme solution containing chymotrypsin and trypsin before and after mixing with PEG600-inhibitor conjugate (D) was done using ODS column (ODS-100s; Tosoh, Japan) with acetonitrile-TFA as a mobile phase. The elution was monitored at 280 nm, and the ‰ow rate and column temperature were 0.3 ml W min and 259 C, respectively. the PEG600-inhibitor conjugate at 259 C (Fig. 2C) , indicating that chymotrypsin can be separated from the solution due to the reaction with the water-insoluble PEG600-inhibitor conjugate. Under these experimental conditions, about 11 nmol of chymotrypsin was removed by 1 mg of the PEG600-inhibitor conjugate. On the other hand, in our previous separation system using the Phe-type phosphonate inhibitor-immobilized Sepharose gel, only about 0.3 nmol of chymotrypsin could be removed by 1 mg of the inhibitor-immobilized gel. 4) This increase of e‹ciency of the PEG600-inhibitor conjugate should result from an increase in enzyme accessibility of the inhibitor moiety due to the introduction of PEGs.
To evaluate the selectivity in the separation, the PEG600-inhibitor conjugate stock solution (10 ml) was mixed with 90 ml of sample solution containing chymotrypsin and trypsin (each 0.3 mg W ml of 20 mM Tris-HCl buŠer, pH 7.0) and incubated for 20 min at 259 C. After centrifugation, a portion (20 ml) of the supernatant was analyzed on a reversed-phase HPLC column, as shown in Fig. 2D -II. Chymotrypsin and trypsin peaks are seen at 21.5 and 23.3 min, respectively, in the control (Fig. 2D-I ). The chymotrypsin peak clearly disappeared but the trypsin peak remained after mixing with PEG600-inhibitor conjugate, indicating that chymotrypsin was selectively precipitated by the PEG600-inhibitor conjugate. Similarly, chymotryptic activity in the supernatant was not detected but the 90z of tryptic activity remained (data not shown). All of these results indicate that chymotrypsin can be selectively separated by the PEG600-inhibitor conjugate due to formation of the precipitate.
Components in the precipitate formed by mixing of the PEG600-inhibitor conjugate with chymotrypsin were analyzed by gel-ˆltration HPLC and MALDI-TOF-MS. The precipitate was dissolved in DMSO and the components were analyzed by HPLC. Figure 3A shows that there are two components (11.0 and 12.2 min) related to chymotrypsin, because the peak at 12.2 min was identiˆed with that of chymotrypsin. The component corresponding to theˆrst peak at 11.0 min should have a larger molecular mass than that of chymotrypsin. In the MALDI-TOF-MS analysis of the precipitate, two molecular mass peaks were detected at around 25,288, and 50,670 m W z, as shown in Fig. 3B . This result suggests that the component for theˆrst peak is a dimeric chymotrypsin cross-linked by the PEG600-inhibitor conjugate containing two phosphonate moieties.
In conclusion, we succeeded in the preparation of water-insoluble PEG-inhibitor conjugates using a Phe-type diphenyl a-aminoalkylphosphonate as an irreversible inhibitor for chymotrypsin-like serine proteases, and we demonstrated that the PEG600-inhibitor conjugate is useful for separation of chymotrypsin due to the formation of the precipitate. Moreover, the route for synthesis of the PEG-inhibitor conjugate can be used for preparation of other PEG-inhibitor conjugates with various substrate speciˆcities by changing the aldehydes used in the amidoalkylation reaction of triphenyl phosphite. The elution conditions were the same as those described in the legend to Fig. 2 . For MALDI-TOF-MS, a-cyano-4-hydroxycinnamic acid was used as a matrix.
